IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO. (June 2017) - Wang, M.L.; Lee, H.; Thirumurthi, S.; Chuang, H.; Hagemeister, F.; Westin, J.; Fayad, L.; Samaniego, F.; Turturro, F.; Chen, W.; Oriabure, O.; Feng, L.; et al.